METHAMPHETAMINE EFFECTS IN BRAIN DOPAMINE ACTIVITY

甲基苯丙胺对大脑多巴胺活动的影响

• 批准号: 7606174
• 负责人: LYNNE T SMITH
• 金额: $ 0.5万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606174
• 关键词: Adult; Brain; Cell physiology; Cells; Computer Retrieval of Information on Scientific Projects Database; Consent; Development; Disease; Dopamine; Drug Metabolic Detoxication; Functional disorder; Funding; Grant; Institution; Knowledge; Laboratories; Los Angeles; Methamphetamine; New York; Oregon; Parkinson Disease; Pharmaceutical Preparations; Positron-Emission Tomography; Recruitment Activity; Research; Research Personnel; Resources; Site; Source; United States National Institutes of Health; Week; Withdrawal; Work; neuroimaging

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study proposed to study methamphetamine using adults using PET imaging during early withdrawal (>2 weeks and <3 months) and again 6-9 months later. The PET imaging will be conducted at Brookhaven National Laboratories in New York under the direction of Dr. Nora Vollow. Methamphetamine is not a drug commonly abused in the eastern U.S. Hence, recruiting for the 40 subjects will occur in Los Angeles at Harbor-UCLA and Portland, Oregon where methamphetamine abuse is a significant problem. Normal controls will not be recruited at the Harbor-UCLA site. The subjects will be recruited, screened, consented and then flown to New York for the neuroimaging studies. This project is an extension to previous work conducted at Harbor-UCLA funded by an NIH/NIDA RO1 grant (Brookhaven National Laboratory Subcontract), 10/01/97-11/30/00. The working hypotheses are: 1) METH abusers will have decreased function of DA cells in addition to the loss of DAT. 2) Detoxification will result in an increase in DA cell function and in DAT levels. It is important to assess if there is disrupted DA cell function in METH abusers since it could perpetuate METH use as a means to temporarily compensate for this dysfunction. It is also of relevant to determine if it recovers with detoxification in order to understand the long-term consequences of DAT losses in the METH abusers vis-a-vis their vulnerability to neurogenerative diseases (i.e., Parkinson's disease). Such knowledge should help guide the management of the METH abuser and the development of medications that may help ameliorate the DA deficits.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究建议在早期戒断（>2周和<3个月）和6-9个月后再次使用PET成像研究成人甲基苯丙胺。PET成像将在纽约的布鲁克海文国家实验室在诺拉沃洛博士的指导下进行。甲基苯丙胺在美国东部并不是一种常被滥用的药物。因此，将在Harbor-UCLA的洛杉矶和俄勒冈州的波特兰招募40例受试者，在这些地区，甲基苯丙胺滥用是一个严重的问题。Harbor-UCLA研究中心不会招募正常对照。受试者将被招募、筛选、同意，然后飞往纽约进行神经影像学研究。该项目是以前在Harbor-UCLA进行的工作的延伸，由NIH/NIDA RO 1赠款（Brookhaven国家实验室分包合同）资助，10/01/97-11/30/00。 工作假设是：1）METH滥用者除了DAT丧失外，DA细胞的功能也会降低。2）去甲肾上腺素会导致DA细胞功能和DAT水平的增加。重要的是要评估是否有破坏DA细胞的功能在METH滥用者，因为它可以永久使用METH作为一种手段，暂时弥补这种功能障碍。确定它是否随着解毒而恢复也是相关的，以便了解甲基苯丙胺滥用者中DAT损失相对于他们对神经变性疾病的脆弱性的长期后果（即，帕金森氏病）。这些知识应该有助于指导METH滥用者的管理和可能有助于改善DA缺陷的药物的开发。